ImmTune Therapies
Develops a targeted nanoparticle delivery platform for in‑vivo genetic engineering of patient cells. The technology is designed to transport nucleic acid payloads (DNA, mRNA) and programmable targeting ligands to specific cell types (first focus: T cells for CAR gene delivery) with the aim of enabling scalable, lower‑complexity cell and gene therapies and accelerating preclinical-to-clinical translation through partnerships.
Industries
Nr. of Employees
small (1-50)
ImmTune Therapies
Products
In vivo CAR gene delivery to T cells (preclinical)
A nanoparticle‑based approach to deliver CAR genes to T cells directly in vivo to generate CAR‑T cells without ex vivo manufacturing.
In vivo CAR gene delivery to T cells (preclinical)
A nanoparticle‑based approach to deliver CAR genes to T cells directly in vivo to generate CAR‑T cells without ex vivo manufacturing.
Services
Partnership engagements to develop targeted nanoparticle delivery solutions and co‑develop payload/delivery combinations for specific therapeutic goals.
Partnership engagements to develop targeted nanoparticle delivery solutions and co‑develop payload/delivery combinations for specific therapeutic goals.
Expertise Areas
- In vivo nanoparticle delivery
- Gene delivery and genetic engineering
- Nanoparticle formulation and functionalisation
- Formulation stability and lyophilisation
Key Technologies
- Targeted nanoparticle vectors
- mRNA and DNA delivery
- Ligand functionalisation for cell targeting
- Lyophilisation and stability testing
News & Updates
Presented technology development and participated in a panel on in vivo genetic engineering at the CAR‑TCR Summit in Boston.
Attended the Onco Cell Therapy Summit in Amsterdam to present and network on cell therapy delivery approaches.
CEO invited as expert faculty to discuss platform technology and preclinical updates at the in vivo engineering summit in Boston.
Received a Biomedical Catalyst grant to develop the delivery vector technology and advance readiness for clinical trials in collaboration with academic and translational partners.
CEO recognised as a Women in Innovation award recipient, a programme providing funding, coaching and mentoring to support business growth.
Imperial College and Innovate UK hosted a Purple Plaque unveiling honouring the company's founder and recognising the company's pioneering work in scalable in vivo cell engineering.
Presented technology development and participated in a panel on in vivo genetic engineering at the CAR‑TCR Summit in Boston.
Attended the Onco Cell Therapy Summit in Amsterdam to present and network on cell therapy delivery approaches.
CEO invited as expert faculty to discuss platform technology and preclinical updates at the in vivo engineering summit in Boston.
Received a Biomedical Catalyst grant to develop the delivery vector technology and advance readiness for clinical trials in collaboration with academic and translational partners.
CEO recognised as a Women in Innovation award recipient, a programme providing funding, coaching and mentoring to support business growth.
Imperial College and Innovate UK hosted a Purple Plaque unveiling honouring the company's founder and recognising the company's pioneering work in scalable in vivo cell engineering.